Description
Introduction: Everecan, crafted by Miracalus Pharma Pvt. Ltd., stands as a pivotal medication containing Everolimus as its active ingredient. Renowned for its efficacy in combating various types of cancer and certain non-cancerous conditions, Everecan offers individuals a beacon of hope in their battle against diseases affecting vital organs.
Active Substance: Everecan’s primary active substance is Everolimus, a potent inhibitor of the mammalian target of rapamycin (mTOR) pathway. Everolimus belongs to the class of mTOR inhibitors and exhibits antiproliferative and immunosuppressive properties. By targeting aberrant signaling pathways involved in cell growth and angiogenesis, Everolimus helps restrain the progression of cancer and certain benign tumors.
Formulation and Packaging: Everecan is available in tablet form, with each tablet containing 5 mg of Everolimus. The tablets are meticulously formulated for oral administration, ensuring precise dosing and optimal absorption. The packaging is designed to maintain the stability and integrity of the medication, with clear labeling indicating the dosage strength, active ingredient, and manufacturer.
Indications: Everecan is indicated for the treatment of various malignancies and non-cancerous conditions, including:
- Advanced Renal Cell Carcinoma (RCC): Everecan is used in combination with other anticancer agents for the treatment of advanced RCC, a type of kidney cancer. Everolimus helps inhibit tumor growth and delay disease progression in patients with metastatic RCC.
- Advanced Hormone Receptor-positive, HER2-negative Breast Cancer: Everecan is prescribed in combination with exemestane for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer. Everolimus helps overcome resistance to endocrine therapy and improves progression-free survival in this patient population.
- Pancreatic Neuroendocrine Tumors (pNET): Everecan is indicated for the treatment of well-differentiated, nonfunctional pNET that is unresectable, locally advanced, or metastatic. Everolimus helps slow tumor growth and may improve progression-free survival in patients with pNET.
Mechanism of Action: Everolimus exerts its therapeutic effects by inhibiting the activity of the mammalian target of rapamycin (mTOR), a key regulator of cell growth, proliferation, and angiogenesis. By blocking the mTOR pathway, Everolimus suppresses tumor cell proliferation, induces cell cycle arrest, and inhibits angiogenesis, thereby impeding tumor growth and metastasis. Additionally, Everolimus exhibits immunosuppressive effects, making it useful in the prevention of organ rejection following transplantation.
Dosage and Administration: The recommended dosage of Everecan (Everolimus 5 mg tablets) may vary depending on the specific indication and individual patient factors. It is essential to follow the dosage and administration instructions provided by a healthcare professional to ensure safe and effective treatment outcomes. Everecan is typically taken orally once daily, with or without food, as directed by a healthcare provider.
Safety Considerations: While Everecan (Everolimus) is generally well-tolerated, it may cause certain side effects in some individuals. Common side effects may include stomatitis (mouth sores), rash, diarrhea, fatigue, and infections. Rare but more severe side effects such as interstitial lung disease, renal toxicity, and metabolic disturbances may occur and require medical attention. Patients should be monitored regularly for signs of adverse effects, and appropriate supportive care measures may be implemented as needed.
Conclusion: Everecan, containing Everolimus as the active substance, serves as a valuable tool in the treatment of various malignancies and non-cancerous conditions. By targeting aberrant signaling pathways involved in cell growth and angiogenesis, Everolimus helps restrain tumor progression and improve outcomes in patients with advanced cancer. As with any medication, it is essential for patients to use Everecan under the supervision of a healthcare professional and to adhere to prescribed dosage and administration guidelines to ensure safe and effective treatment outcomes.
Reviews
There are no reviews yet.